4 news items
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
HOTH
27 Mar 24
in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
HOTH
27 Mar 24
to leveraging top-tier computational resources and AI expertise to advance its research and development efforts in therapeutic discovery
Hoth Therapeutics Announces Data In Completed Study Of Alzheimer's Disease Pre-Clinical Treatment With HT-ALZ
HOTH
19 Mar 24
.Hoth Therapeutics remains committed to further research and development of HT-ALZ, including detailed analyses of its effects on microglial
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
HOTH
19 Mar 24
committed to further research and development of HT-ALZ, including detailed analyses of its effects on microglial activation and brain inflammation
- Prev
- 1
- Next